CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance-Reference-Cited by-同舟云学术

CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance

Published:2014-06-09 Issue:7 Volume:124 Page:3003-3015
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:J. Clin. Invest.

Author:

Park Kang-Seo,Raffeld Mark,Moon Yong Wha,Xi Liqiang,Bianco Caterina,Pham Trung,Lee Liam C.,Mitsudomi Tetsuya,Yatabe Yasushi,Okamoto Isamu,Subramaniam Deepa,Mok Tony,Rosell Rafael,Luo Ji,Salomon David S.,Wang Yisong,Giaccone Giuseppe

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference64 articles.

1. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

2. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

3. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

4. Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer

5. Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploiting a tumor softening targeted bomb for mechanical gene therapy of chemoresistant Triple-Negative breast cancer;Chemical Engineering Journal;2024-10

2. DUSP5 regulated by YTHDF1-mediated m6A modification promotes epithelial-mesenchymal transition and EGFR-TKI resistance via the TGF-β/Smad signaling pathway in lung adenocarcinoma;Cancer Cell International;2024-06-13

3. Exploiting a Tumor Softening Targeted Bomb for Mechanical Gene Therapy of Chemoresistant Triple-Negative Breast Cancer;2024

4. Root Extract of Trichosanthes kirilowii Suppresses Metastatic Activity of EGFR TKI-Resistant Human Lung Cancer Cells by Inhibiting Src-Mediated EMT;Nutrition and Cancer;2023-10-23

5. The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies;Pharmaceutics;2023-05-27